NASDAQ · Biotechnology

BIOA (BIOA) Stock

$20.88 -4.09% NASDAQ: BIOA Healthcare

Valuation

MetricValue
Price$20.88
Market Cap$786.12M
P/E Ratio-9.34
P/B Ratio2.25
P/S Ratio70.29
EPS (TTM)$0.00
52-Week High$25.87
52-Week Low$4.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-25.98%
ROA-17.15%
ROCE-34.19%
Gross Margin99.39%
Operating Margin-9.86%
Net Margin-8.72%
Debt/Equity0.01
Current Ratio14.35

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$9.0M
Operating Profit$-40.0M$-48.0M$-78.0M$-93.0M
Net Profit$-40.0M$-64.0M$-71.0M$-81.0M
EPS$-1.16$-1.87$-1.98$-2.24
Op Margin———-1031.5%

Balance Sheet (USD)

Metric2022202320242025
Total Assets$28.0M$26.0M$358.0M$295.0M
Total Liabilities$141.0M$199.0M$35.0M$23.0M
Cash$28.0M$22.0M$354.0M$189.0M
Borrowings$2.0M$53.0M$9.0M$6.0M

Latest News

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 PR Newswire · Jul 14, 2026 HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction PR Newswire · Jul 14, 2026 Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing MT Newswires · Jul 1, 2026 Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? Insider Monkey · Jun 30, 2026 BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor Simply Wall St. · Jun 25, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-36.0M$-37.0M$-52.0M$-82.0M
Investing Cash Flow$0$0$-1.0M$-96.0M
Financing Cash Flow$0$0$-4.0M$0
Net Cash Flow$-34.0M$-3.0M$329.0M$-165.0M
Free Cash Flow$-36.0M$-38.0M$-52.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-4.17
FCF Yield-12.22%
Quick Ratio24.76
Interest Coverage-93.00
Return 1Y351.55%
Return 3Y—
Return 5Y—

Ownership

Insiders Held2.44%
Institutions Held85.17%
Institutions Float Held87.30%
Institutional HolderSharesReport Date
a16z Capital Management, L.L.C.3,233,1702026-03-31
Cormorant Asset Management, LP2,890,6052026-03-31
Sofinnova Investments, Inc.2,293,7882026-03-31
Blackrock Inc.2,267,7562026-03-31
Janus Henderson Group PLC2,094,2702026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACB $2.72 -0.73% 115.33 $168.48M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%
CGC $0.92 +4.02% -0.20 $390.20M 0.00%

About BIOA

BIOA is led by CEO Kristen Fortney, publicly traded since 2024.

BIOA stock trades at $20.88 with a market capitalization of $786.12M. The stock is valued at a price-to-earnings (P/E) ratio of -9.34, price-to-book of 2.25, price-to-sales of 70.29. Over the past 52 weeks the stock has ranged between $4.07 and $25.87, and currently trades 19.3% below its 52-week high.

On profitability, BIOA generates a return on equity (ROE) of -25.98%, return on capital employed of -34.19%, an operating margin of -9.86%, a net profit margin of -8.72%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides